The European Medicines Agency (EMA) has accepted for review Amarin’s (NASDAQ:AMRN) marketing application seeking approval for icosapent ethyl (brand name Vascepa in the U.S.) as a treatment to reduce the risk of cardiovascular events in high-risk patients who have their cholesterol levels controlled with statin treatment but have elevated triglycerides.
The EMA expects to complete the review procedure before the end of 2020.
Shares are up 2% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.